POMPANO BEACH, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC:BSEM), a leading medtech company specializing in the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, announced today that it will release its second quarter 2024 financial results after the market close on Monday, August 12, 2024. The company will also host a conference call and webcast at 4:30 PM ET to discuss the results. The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Michael Fortunato, CFO. To register for the event, please click HERE. Conference Call & Webcast Information: USA / International Toll: +1 (646) 307-1963 USA - Toll-Free: (800) 715-9871 Canada – Toronto: (647) 932-3411 Canada - Toll-Free: (800) 715-9871 Webcast Link: https://events.q4inc.com/attendee/133546543 The live and archived webcast of the call will also be available on the BioStem Technologies website under the Investors section or by clicking HERE. About BioStem Technologies, Inc. (OTC:BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and ...